Department of Critical Care Medicine, Rongcheng People's Hospital, Rongcheng, Shandong, China.
Department of MedicalInsurance, Weihai Hospital of Traditional Chinese Medicine, Weihai, Shandong, China.
Folia Neuropathol. 2022;60(4):421-426. doi: 10.5114/fn.2022.118787.
The aim of the study was to investigate the effectiveness of alteplase intravenous thrombolysis combined with butylphthalide in patients with severe cerebral infarction.
From February 2018 to March 2019, 100 patients with severe cerebral infarction in Rongcheng People's Hospital were recruited and randomly divided into two groups, i.e., alteplase intravenous thrombolysis treatment group and alteplase intravenous thrombolysis combined with butylphthalide treatment group. The efficacy of treatment methods was compared between the two groups by analyzing National Institutes of Health Stroke Scale (NIHSS) scores of patients on the first, seventh, and fourteenth days after treatment. Quality of life of patients was evaluated using Barthel scale before and after treatment, and also, the incidence of adverse reactions was compared between the two groups.
The therapeutic effect and quality of life in the alteplase intravenous thrombolysis combined with the butylphthalide group were better compared with patients in the alteplase intravenous thrombolysis group. The total effective rate of the alteplase intravenous thrombosis group was 80%, and that of the alteplase intravenous thrombosis combined with butylphthalide group was 100%; the latter treatment was more effective (p < 0.05). NIHSS scores of the patients at 1, 7, and 14 days after treatment were better in the former group than in the latter (p 0.05). In other words, the combination of drugs did not increase the incidence of adverse reactions.
Alteplase intravenous thrombolysis combined with butylphthalide in the treatment of severe cerebral infarction is safe, and may significantly improve patient's neurological function and quality of life without adverse reactions.
本研究旨在探讨阿替普酶静脉溶栓联合丁苯酞治疗严重脑梗死的疗效。
2018 年 2 月至 2019 年 3 月，我院收治 100 例严重脑梗死患者，随机分为阿替普酶静脉溶栓治疗组和阿替普酶静脉溶栓联合丁苯酞治疗组。通过分析两组患者治疗后第 1、7、14 天 NIHSS 评分比较两组治疗方法的疗效。采用巴塞尔量表评价治疗前后患者的生活质量，比较两组不良反应发生率。
阿替普酶静脉溶栓联合丁苯酞组的治疗效果和生活质量均优于阿替普酶静脉溶栓组。阿替普酶静脉溶栓组总有效率为 80%，阿替普酶静脉溶栓联合丁苯酞组为 100%；后者治疗效果更显著（p<0.05）。治疗后 1、7、14 天患者 NIHSS 评分均优于前者（p<0.05）。也就是说，联合用药并没有增加不良反应的发生率。
阿替普酶静脉溶栓联合丁苯酞治疗严重脑梗死安全，可显著改善患者神经功能和生活质量，且无不良反应。
